Top Markets
Coin of the day
Hepion Pharmaceuticals, Inc. Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc.

HEPA
Classificação em ações #39072
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is... Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
Preço da ação
$0.0568
Última sincronização: 2026-08-13
Valor de mercado
$661.36K
Variação (1 dia)
11.37%
Variação (1 ano)
-5.33%
País
US
Negociar Hepion Pharmaceuticals, Inc. (HEPA)

Categoria

Rácio P/S de Hepion Pharmaceuticals, Inc. (HEPA)
Rácio P/S em 2026 TTM: 0
De acordo com os relatórios financeiros mais recentes e o preço das ações da Hepion Pharmaceuticals, Inc., o rácio P/S atual (TTM) é 0. No final de 2026, o rácio P/S era 0.
Histórico do rácio P/S da Hepion Pharmaceuticals, Inc. de 2026 a 2026
Rácio P/S no final de cada ano
Ano Rácio P/S Alterar
Não há dados suficientes para as datas fornecidas.
Rácio P/S de empresas semelhantes ou concorrentes
Empresa Rácio P/S Diferença do rácio P/S País
9.88 -
US
10.30 -
NL
- -
CH
- -
KR
4.98 -
BE